Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (949)	11/17/1997 11:56:00 PM
From: D.Right	Read Replies (1) \| Respond to of 2173

Dear Henry: The reason AMLN has to change the the duration of two of their trials is not because the drug is not working, it is because they didn't design their first two trails very well. If the drug is not working, it doesn't matter how long the trial is, it is not going to work. It is true the reality is Wall Street doesn't like the delay. I don't like it either. But with a drug of pramlintide's potential, AMLN will survive this downturn (tax selling, shorts to push it down whatever). As for the replacement vs. add on, you don't have to agree with me. I have never asked you to agree with me, it was you who kept saying I was wrong. Let's just leave it as it is. D.Right